SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VIVS

VivoSim Labs, INC. (NASDAQ:VIVS)

US · Delayed Price · Currency is USD
Also listed: ONVO, 0R02.LHealthcare · Biotechnology
$0.26-$0.03 (-10.53%)
 
Market cap
$4.33M
Insider Score
Health Score
Listed since
Feb 14, 2012
Website
Market Cap$4.33M-88.4%
Revenue (ttm)$135.00K-3.6%
Net Income-$10.27M-417.8%
EPS-$0.62-235.6%
Shares Out16.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume147,188,469
Open$0.28
Previous Close$0.29
Day's Range$0.25 - $0.38
52-Week Range$0.12 - $3.40
Beta1.56
Analystsn/a
Price Targetn/a
Earnings DateFeb 9, 2027

About VIVS

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Address
11555 Sorrento Valley Road, San Diego, CA, 92121, US
Market Cap
4 million
Employees
15
Industrial Classification
Biotechnology

VivoSim Labs, INC. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
1st Percentile Overall Score
VIVS InsiderScore:24 / 99

VivoSim Labs, INC. scored higher than 1% of companies evaluated by InsiderBuying, and ranked 105th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at VivoSim Labs, INC. bought $2.8K of stock across 1 purchase in the last 90 days, the largest of them $2.8K.

Stake Increase

None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$7.32K
Bought
$2.80K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From VIVS’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-10.53%
5 Days
+99.85%
1 Month
+63.61%
6 Months
-80.82%
1 Year
-88.41%

$VIVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VIVS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VIVS's directors and management

Net Shares Purchased by Insiders−10k−5k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VIVS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

VIVS Revenue by Segment

$291.00KTotal
Non-cash stock-based compensation$235.00K80.76%
Cost of services provided$56.00K19.24%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New VIVS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VIVS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VIVS

VXFVanguard Extended Market ETF$2.38K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VIVS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
71% of score
23.64
Analyst Ratings
No data yet
—
News & Sentiment
29% of score
78

News check: Multiple major contract wins with pharmaceutical companies and upward revenue guidance revisions signal strong business momentum and positive momentum.

Recent Insider Activity

Buys
1
Sells
1
Buy Value
$2.80K
Distinct Buyers
1

Insider Score Trend Over Time

+10.0 since Sep 24
0255075100Sep 24 — Insider Score 13.6Sep 25 — Insider Score 38.3Sep 26 — Insider Score 37.8Sep 27 — Insider Score 38.0Sep 28 — Insider Score 38.1Sep 29 — Insider Score 37.6Sep 30 — Insider Score 37.3Oct 1 — Insider Score 36.4Oct 2 — Insider Score 31.0Oct 3 — Insider Score 36.1Oct 4 — Insider Score 36.4Oct 5 — Insider Score 36.5Oct 6 — Insider Score 35.6Oct 7 — Insider Score 35.2Oct 8 — Insider Score 35.0Oct 9 — Insider Score 34.8Oct 10 — Insider Score 34.3Oct 11 — Insider Score 35.4Oct 12 — Insider Score 35.5Oct 13 — Insider Score 35.2Oct 14 — Insider Score 35.7Oct 15 — Insider Score 35.7Oct 16 — Insider Score 35.4Oct 17 — Insider Score 35.4Oct 18 — Insider Score 35.8Oct 19 — Insider Score 35.6Oct 20 — Insider Score 35.7Oct 21 — Insider Score 35.6Oct 22 — Insider Score 35.6Oct 23 — Insider Score 35.6Oct 24 — Insider Score 35.5Oct 25 — Insider Score 35.1Oct 26 — Insider Score 35.3Oct 27 — Insider Score 35.3Oct 28 — Insider Score 35.3Oct 29 — Insider Score 35.0Oct 30 — Insider Score 34.0Oct 31 — Insider Score 33.6Nov 1 — Insider Score 33.9Nov 2 — Insider Score 33.9Nov 3 — Insider Score 33.5Nov 4 — Insider Score 33.2Nov 5 — Insider Score 32.5Nov 6 — Insider Score 31.7Nov 7 — Insider Score 31.1Nov 8 — Insider Score 32.0Nov 9 — Insider Score 32.5Nov 10 — Insider Score 31.4Nov 11 — Insider Score 30.4Nov 12 — Insider Score 30.4Nov 13 — Insider Score 29.3Nov 14 — Insider Score 28.6Nov 15 — Insider Score 29.1Nov 16 — Insider Score 29.0Nov 17 — Insider Score 26.9Nov 18 — Insider Score 26.1Nov 19 — Insider Score 25.0Nov 20 — Insider Score 23.6Nov 21 — Insider Score 23.0Nov 22 — Insider Score 23.6Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.